CytomX Therapeutics Inc
$ 3.46
2.67%
07 Aug - close price
- Market Cap 729,305,000 USD
- Current Price $ 3.46
- High / Low $ 3.55 / 3.31
- Stock P/E N/A
- Book Value 1.47
- EPS -0.52
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.34 %
- 52 Week High 8.21
- 52 Week Low 1.72
About
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$12.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-03-16 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-11 | 2023-11-07 |
| Reported EPS | -0.09 | -0.1 | -0.22 | -0.09 | -0.0012 | 0.27 | 0.23 | 0.07 | -0.08 | 0.17 | 0.01 | 0.04 |
| Estimated EPS | -0.11 | -0.11 | -0.0937 | -0.04 | -0.06 | 0.1322 | -0.11 | -0.13 | -0.06 | -0.06 | -0.03 | -0.21 |
| Surprise | 0.02 | 0.01 | -0.1263 | -0.05 | 0.0588 | 0.1378 | 0.34 | 0.2 | -0.02 | 0.23 | 0.04 | 0.25 |
| Surprise Percentage | 18.1818% | 9.0909% | -134.7919% | -125% | 98% | 104.236% | 309.0909% | 153.8462% | -33.3333% | 383.3333% | 133.3333% | 119.0476% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTMX
2026-08-07 04:41:21
CytomX Therapeutics (CTMX) is progressing its lead asset, Varetta M, an EPCAM-targeting ADC, towards a registrational study in late-line colorectal cancer by H1 2027, with positive preliminary PFS data. Despite a significant revenue decrease and increased operating expenses in Q2 2026, the company maintains a strong financial runway until H2 2028 and is expanding Varetta M's potential to other GI cancers. Key challenges include managing grade 3 diarrhea rates for Varetta M and finalizing the registrational study's design (third vs. fourth line CRC), while also expanding collaborations, such as with Regeneron.
2026-08-07 01:41:21
CytomX (NASDAQ: CTMX) reported a significant decline in Q2 2026 revenue to $1.4 million, down from $18.7 million year-over-year, and a widened net loss of $20.7 million primarily due to decreased collaboration revenue and increased R&D spending. Despite the financial setbacks, the company maintained $330.3 million in cash and investments at quarter-end, bolstered by a $37.0 million Regeneron payment in July, extending its cash runway to at least the second half of 2028. CytomX also made progress in its pipeline with Varseta-M and CX-801, expanding clinical trials and collaborations, though early-stage clinical risks and revenue volatility remain key concerns for investors.
2026-08-06 23:41:21
CytomX Therapeutics reported a wider-than-expected Q2 2026 loss and a significant revenue drop, but its stock remained stable due to a strong cash reserve, a new Regeneron milestone payment, and promising early data for its lead cancer drug, Varseta-M. The company is strategically shifting from collaboration-based revenue to a clinical-stage model focused on Varseta-M, extending its cash runway through at least the second half of 2028. Management plans for a registrational study in late-line colorectal cancer and is expanding Varseta-M into other GI cancers, while also advancing its CX-801 program.
2026-08-06 20:41:21
CytomX Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The report is available through Refinitiv, and the full article can be accessed by TradingView users. This news was originally reported by Reuters.
2026-08-06 20:41:21
CytomX Therapeutics reported Q2 2026 results with $1.4 million in revenue and $25.2 million in operating expenses, resulting in a $23.8 million operating loss. The company holds $330.3 million in cash, equivalents, and investments, projecting a financial runway until at least the second half of 2028. Key updates include progress on their Varsetatug masetecan (Varseta-M) and CX-801 programs, alongside an expanded collaboration with Regeneron.
2026-08-06 20:40:07
CytomX Therapeutics Inc (NASDAQ: CTMX) reported second-quarter earnings per share of $-0.090, missing the analyst estimate of $-0.080. The company's revenue for the quarter was $1.41 million, falling significantly short of the consensus estimate of $11.33 million. Despite the earnings miss, the stock is up 60.710% in the last 12 months, although it has declined by -15.200% in the last 3 months.
